AmSurg Shares Rise in Value After $2.35B Sheridan Deal Announcement

Raymond James analyst John Ransom set AmSurg’s price target at $60 and upgraded his recommendation to “buy,” according to a Value Walk report.

Advertisement

The upgrade was made closely following AmSurg’s announcement of intention to acquire Sheridan Healthcare for $2.35 billion.

More Articles on Transactions and Valuation Issues:
4 Recent ASC Industry Acquisitions
Beloit Health System ASC Project Remains in Limbo
3 Recently Opened & Expanded Ambulatory Surgery Centers

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.